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Abstract
Elevated levels of ubiquitin C-terminal hydrolase L1 (UCH L1) have been detected in a variety of 
malignancies, and recent studies show the oncogenic capacity of overexpressed UCH L1 in vivo in 
animal models. Here we demonstrate that expression of endogenous UCH L1 is significantly 
higher in B-lymphoma cells than in transformed cells of epithelial and fibroblastic origin. The 
specific hematopoietic transcription factor PU.1 induces UCH L1 expression through direct 
activation of the uch l1 promoter. Using chromatin immunoprecipitation (ChIP) assays and direct 
mutagenesis we identified PU.1 binding sites on the uch l1 promoter, at least three of which are 
involved in this activation. We also show that the viral transcriptional co-activator EBNA2 
dramatically increases PU.1-dependent up-regulation of endogenous UCH L1 expression. Finally, 
inhibition of PU.1 expression with specific shRNA resulted in reduction of UCH L1 mRNA and 
protein levels in Epstein–Barr virus (EBV)-transformed B-cells. We propose that the ubiquitin-
editing enzyme UCH L1 is a multifunctional pro-oncogenic factor involved in development and 
progression of certain lymphoid malignancies, including EBV-associated lymphomas.
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Introduction
There are few known representatives of the small group of deubiquitinating enzymes named 
ubiquitin C-terminal hydrolases, UCHs. They are relatively small proteins (25–75 kDa) with 
approximately 50% sequence homology among the members [1]. Among them is ubiquitin 
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C-terminal hydrolase L1 (UCH L1), a cysteine hydrolase that contains the typical active-site 
triad of cysteine, histidine, and aspartic acid and catalyzes hydrolysis of C-terminal esters 
and amides of ubiquitin [2]. Normally UCH L1 is expressed abundantly (and almost 
exclusively) in brain tissue. Although the physiological function of UCH L1 in neurons is 
still unclear, mutations in the UCH L1 gene have been associated with Parkinson and 
Alzheimer diseases [3]. UCH L1 has also been shown to function as a ubiquitin ligase in its 
dimeric form [4], and as a stabilizer of mono-ubiquitin in neurons [5].
Recent studies indicate that UCH L1 is involved in regulation of cytoskeletal dynamics: it 
affects tubulin polymerization [6,7], and alters the dynamics of actin filaments during 
bacterial invasion [8]. Moreover, the recently discovered association of UCH L1 with 
mitotic spindle microtubules suggests a functional role of general significance for this 
protein during mitosis [7].
Increased levels of UCH L1 have been detected in cancers of different cellular and tissue 
origin such as lung [9], colorectal [10], bladder [11], and breast cancer [12], suggesting its 
involvement in oncogenesis. Indeed, several studies demonstrate that inhibition of UCH L1 
expression reduces the tumorigenic phenotype of transformed cells [13–15]. Recently two 
independent in vivo studies provided strong evidence that UCH L1 is an oncogene: 
transgenic mice with overexpressed UCH L1 develop tumors [16], and pulmonary 
metastasis of cancer cells in nude mice can be suppressed by inhibition of UCH L1 
expression [15]. These distinct studies indicate that this multifunctional protein of the 
ubiquitin system is involved in diverse cellular processes, and that the specific physiological 
roles of UCH L1 and regulation of its expression in transformed cells need further analyses.
Elevated levels of UCH L1 RNA in malignant tumor cells indicate that the uch l1 gene is 
subject to regulation during cellular transformation by oncogenic transcription factors. The 
minimal uch l1 promoter region has been mapped to a 233 bp region that possesses binding 
sites for neuron-specific transcription factors such as OCT and PSN, which regulate UCH 
L1 expression in neurons [17]. Indeed, B-Myb, a transcription factor implicated in 
regulation of the cell cycle, has been shown to stimulate expression of murine uch l1 on the 
promoter level in vitro and in vivo [18]. Additionally, we have shown that the β-catenin/T-
cell factor (TCF) transcription complex stimulates expression of the uch l1 gene [19].
UCH Ll-expressing transgenic mice are susceptible to spontaneous lymphomas, and UCH 
L1 overexpression accelerated lymphomagenesis in Eµ-myc transgenic mice [16]. High 
levels of UCH LI were also observed in transformed cells of lymphoid origin, including 
Burkitt lymphomas [13,20].
Analysis of the uch l1 promoter sequence revealed five putative PU.1 binding sites. The 
transcription factor PU. 1 belongs to the Ets family and contains the Ets domain as a DNA-
binding region [21]. Expression of PU.1 is restricted in the hematopoietic system: it 
activates gene expression during myeloid and B-lymphoid cell development [22,23]. Studies 
in PU.1 knockout mice have shown that it is required for the development of macrophages, 
B-cells, and neutrophils, as well as dendritic cells [24,25]; PU.1 has been shown to regulate 
the expression of a growing list of genes in each of these lineages [23]. PU.1 functions as an 
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oncogene in Friend virus-induced erythroleukemia and as a tumor suppressor in acute 
myeloid leukemias [26,27]. Additionally, PU.1 is up-regulated in a majority of lymphomas 
including B-cell, Hodgkin, follicular, and mantle cell [28,29].
First isolated from African Burkitt lymphoma, Epstein-Barr virus (EBV) is a DNA tumor 
virus that causes or is closely associated with several malignancies, including B-cell 
lymphomas in which it acts as an etiologic agent or cofactor [30]. EBV can infect and 
transform resting B-cells both in vitro and in vivo, confirming its B-lymphotrophic nature. 
EBV-positive lymphomas include virtually all B-cell post-transplant lymphoproliferative 
diseases and acquired immunodeficiency syndrome (AIDS)-associated lymphomas, a subset 
of Hodgkin lymphomas, and rare T-cell lymphomas [31]. The endemic Burkitt lymphomas 
from Africa are 95% EBV-positive [32]. Among the EBV latency genes, EBV nuclear 
antigen 2 (EBNA2) is crucial for the transformation process [33]. EBNA2 is the major viral 
transcriptional activator in latently infected transformed B-cells, and it activates not only 
viral but also cellular promoters via other transcription factors, one of which is PU.1 [34,35].
In this study we show that the essential hematopoietic transcription factor PU.1 directly up-
regulates the uch l1 gene in transformed B-cells, and that the EBV transactivator EBNA2 
further enhances PU.1-dependent activation of UCH L1 expression. We also show that 
suppression of PU.1 levels reduces endogenous UCH L1 expression in transformed B-cells, 




All adherent cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM; 
Sigma) supplemented with 10% fetal bovine serum (FBS; Sigma) and penicillin–
streptomycin. Burkitt lymphoma cell lines (LCLs) BL30 and BL30-EBV, X-50/7, Raji, and 
KR4 lymphoblastoid cells were cultured in RPMI 1640 medium plus 10% heat-inactivated 
FBS and 100 units/mL penicillin–streptomycin. All cell lines were maintained at 37°C in 
5% CO2 in air.
Plasmid constructs
Wild-type pAG-EBNA2-HA was a gift from Dr. Paul Ling [36], wild type pECE-PU. 1 a 
gift from Dr. Alan Friedman [37], and PU.1 siRNA construct a gift from Dr. Mark Kaplan 
[38]. pGL3-UCH L1 promoter reporter construct was amplified and cloned as described 
earlier [14]. pET-32a PU.1 was a gift from Dr. Michael Ostrowski [39].
Transient transfections and luciferase reporter assay
For luciferase assays, cells were plated in six-well plates and transiently transfected with the 
use of Fugene HD (Roche Diagnostics) with UCHL1p-LUC promoter plasmid, and effector 
plasmid (for concentrations refer to figure legends). The total amount of DNA in all 
transfections was kept constant with empty vector. Luciferase assays were performed 48 h 
post-transfection as specified by the manufacturer (Promega). All reporter assay results are 
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from three independent experiments prepared in triplicate and have been normalized for β-
galactosidase activity.
Reverse transcriptase-PCR
NIH 3T3 cells were transiently transfected with a total of 2 µg of DNA with Fugene HD 
reagent (Roche Diagnostics) according to the manufacturer’s instructions. Cells were 
collected 48 h post-transfection for reverse transcriptase-polymerase chain reaction (RT-
PCR) analysis. Total RNA was extracted with the use of Agilent’s Total RNA isolation mini 
kit as per the manufacturer’s instructions (Agilent Technologies). Five hundred nanograms 
of total RNA were used for RT-PCR reactions with Qiagen’s one step RT-PCR kit (Qiagen) 
as per the manufacturer’s instructions at an annealing temperature of 55°C. Samples were 
analyzed on 1% agarose gel. Primers used were: UCH L1: 5′-GGATGGCC 
ACCTCTATGAAC-3′, 5′-AGACCTTGGCAGCG TCCT-3′; GAPDH: 5′-
AGGTGAAGGTCGG AGTCAACG-3′, 5′-AGGGGTCATTGATGGCA ACA-3′.
Quantitative real-time PCR
Total RNA was extracted from BL30 or BL30-EBV cells and LCLs stably expressing PU. 1 
shRNA or GFP (green fluoresecent protein) shRNA. The reverse transcription reaction was 
performed with 500 ng total RNA using the iScript cDNA synthesis kit per the 
manufacturer’s instructions (Bio-Rad). A 1:25 dilution of cDNA was used in the quantitative 
real-time (QRT)-PCR reaction. QRT-PCR was carried out in a 15 µL reaction mixture with 
gene-specific primers for UCH L1 and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) (also used in RT-PCR) using an iQ-SYBR green kit (Bio-Rad). PCR conditions 
were 95°C for 3 min, 45 cycles at 95°C for 15 s, and 55°C for 45 s on an ABI HT 7600 PCR 
instrument. All samples were assayed in triplicate. Differences in expression of UCH L1 
were evaluated using a relative quantification method in which expression of UCH L1 was 
normalized to the reference gene GAPDH.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) assay was carried out using an Active Motif ChIP-
IT enzymatic kit (Active Motif) as per the manufacturer’s instructions. KR4 cells were fixed 
with 37% formaldehyde (1% final concentration) for 10 min at 37°C; the reaction was 
stopped with cold 0.125 M glycine solution for 5 min at room temperature. The cells were 
then washed twice with phosphate buffered saline solution (PBS) and collected in 0.5 mL of 
digestion buffer with 1 × protease inhibitors. Chromatin was sheared with shearing enzyme 
for 10 min at 37°C to obtain an average of 200–1000 bp fragments. Sheared chromatin was 
incubated overnight at 4°C with Protein G magnetic beads, and PU.1 antibody (Santa 
Cruz-352 X). Immunoprecipitation was performed as per the manufacturer’s instructions; 
cross-linking was reversed by incubating immunoprecipitated complexes with 5 M NaCl and 
RNase A (final concentration 25 µg/mL) for 2 h at 65°C followed by Proteinase-K (final 
concentration 50 µg/mL) treatment for 2 h at 42°C. PCR was performed with 5 µL 
precipitated DNA with primer pairs flanking consensus PU.1 sites in the uch l1 promoter. 
PCR conditions were: one cycle at 95°C for 2 min; 30 cycles at 95°C for 30 s, 55°C for 30 s, 
and 72°C for 2 min, and a final extension at 72°C for 10 min. The primers used in the 
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reaction were: 1500 bp upstream: 5′-CAGTTCCCAAGCTCAGTG-3′, 5′-
CCGGACACATAACCCAGT-3′; site 1: 5′-TC ACTTAAAAACGAACCTCG-3′, 5′-
GAGTCTCT GAAGCATTTGAG-3′; site 2/3: 5′-CAACAAATC CCGTCTCCACA-3′, 5′-
TCGCCGGTGAGATA ATCTGG-3′; site 4/5: 5′-GTACCCATCTGGC CGCGACC-3′, 5′-
CCATCGGCTTGAGCTGCA TC-3′.
Site-directed mutagenesis
The uch l1 promoter construct was mutated at different PU. 1 binding sites with a Quik-
Change Site Directed Mutagenesis Kit (Stratagene). The PU.1 binding site GGAA was 
mutated to CTTC and exactly the same mutations were introduced at all the binding sites. 
Four nucleotide changes were introduced into the parental plasmid by oligonucleotide 
primers carrying the specific mutations. The construct was mutated at a single PU.1 binding 
site or two adjacent binding sites at a time. The parental DNA template was then digested 
with DpnI. All mutations and the integrity of the remainder of the promoter were confirmed 
by DNA sequencing.
Western blotting
Total cell lysates were resolved on 12% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE), transferred to a polyvinylidenefluoride (PVDF) membrane 
(GE Healthcare), blocked in 5% milk-Tris-buffered saline solution, and incubated at 4°C 
overnight with UCH L1 (1:7500; Invitrogen), PU.1 (1:500; SCBT), and GAPDH (1:5000; 
Sigma) antibodies followed with horseradish peroxidase-conjugated secondary antibody. 
Proteins were detected with a Super Signal West Pico Chemiluminescence Detection Kit 
(Pierce Biotechnology) and exposed to Kodak XAR-5 film.
Purification of recombinant PU.1
pET-32a PU.1 was transformed into BL21(DE3) pLysS (Stratagene). The cultures were 
incubated at 37°C and induced with 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG). 
Cells were lysed in 100 µL of FastBreak lysis buffer (Promega) and PU.1 was purified with 
His-Magne Beads (Promega), as per the manufacturer’s instructions. PU.1 was eluted with 
500 mM imidazole, 10% glycerol, and 100 mM HEPES [4-(2-hydroxyethyl)- 1-
piperazineethanesulfonic acid; pH 7.5]. The purity of PU.1 was confirmed by densitometric 
analysis of Coomassie blue-stained 10% SDS-PAGE gel.
Electrophoretic mobility shift assay
Mobility shift assays (Invitrogen, E-33075) were performed using the following double-
stranded oligonucleotides containing PU.1 binding sites and surrounding sequences from the 
human uch l1 promoter [Figure 2(A)]: site 1: 3′-ACTTAACATG-
GAGGAGGAATTGTCTA AGGTTAA-5′; site 2: 5′-
TTGGGCGAAGTTTCTGGAAACCCATCCT TTCACCA-3′; site 3: 3′-
CTGCTCCATACACT-CAAGGAACACCCACCA ACAAAT-5′; site 4: 5′-
GAACCAAGCGAGGGGGAAACGGACGGTCG CGGCC-3′; site 5: 5′-CA 
GAAATAGCCTAGGGAAGACGAAAAACAGCT AG-3′.
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Each PU.1 site was generated using single-stranded oligonucleotides. The oligomers (3 
mg/mL) were annealed to complementary oligomer in 3 mM sodium citrate, pH 7.0, and 30 
mM NaCl at 95°C for 5 min and then cooled slowly to room temperture for several hours.
The annealed oligomers (100 pg) were incubated with or without recombinant PU.1 (200 
ng) in presence of 5×binding buffer (Invitrogen; E33075) for 20 min at room temperature. 
At the end of the reaction, DNA loading dye was added and the reaction was separated on 
4% PAGE in Tris-acetate–ethylenediaminetetraacetic acid (EDTA) (TAE) buffer at 200 V. 
The gel was then stained with SYBR green DNA stain for 20 min, washed with double-
distilled H2O, and visualized using a fluorescence imager at 473 nm excitation and 520 nm 
emission wavelength settings. Next, for detecting PU.1, proteins were transferred onto a 
PVDF membrane and Western blot analysis was performed for PU.1 with anti-PU.1 
antibody (SCBT).
Immunoprecipitation
KR4 cells were lysed with buffer containing 50 mM of Tris-HCl, pH 7.6, 1% NP-40, 0.25% 
sodium deoxycholate, 1 mM EDTA, 1 mM Na3OV4, 1 mM NaF, and complete protease 
inhibitor mixture (Roche Diagnostics). After pre-clearing, cell lysates were incubated with 
PU.1 (SCBT) or control immunoglobulin G (IgG) for 1 h at 4°C; immune complexes were 
then incubated with protein A/G Sepharose beads (Santa Cruz) at 4°C overnight, washed 
four times with protein lysis buffer, and then eluted from protein G Sepharose with 2 × 
Laemmli’s buffer.
Results
UCH L1 levels are elevated in transformed B-cell lines
We compared UCH L1 expression in cells of different origins. Comparison of different 
transformed B-cell lines with transformed epithelial and fibroblastic cell lines demonstrated 
that UCH L1 expression is substantially increased in transformed B-cells versus the other 
cell lines (Figure 1), which suggests a specific role for UCH L1 in lymphoid cancers.
Direct binding of PU.1 on uch l1 promoter in vitro
The uch l1 promoter sequence analysis had revealed five PU.1 putative binding sites. A 
schematic representation of the PU.1 sites is shown in Figure 2(A). We performed 
electrophoretic mobility shift assays (EMSAs) to determine whether PU.1 can bind directly 
to the uch l1 promoter (Figure 2) using recombinant PU.1 purified from Escherichia coli 
[Figure 2(B)] and oligos corresponding to the putative PU.1 sites on the uch l1 promoter. 
Detection of DNA complexes with SYBR green DNA stain [Figure 2(C)] and Western blot 
analysis with PU.1 antibody [Figure 2(D)] showed that PU.1 caused a shift in the mobility of 
dsDNA oligonucleotides representing binding at each of the five PU.1 sites on the promoter, 
indicating that PU.1 directly binds to the uch l1 promoter.
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UCH L1 is regulated at the transcriptional level through PU.1 binding sites in transformed 
B-cell lines
We also tested whether PU.1 could bind to the endogenous uch l1 promoter with ChIP 
assays (see ‘Materials and methods’). Non-immunoprecipitated DNA was used as input 
DNA and normal IgG antibody as negative control. The ChIP data indicate that PU.1 was 
capable of binding the uch l1 promoter on PU.1 sites [Figure 3(A)]; since sites 2 and 3 are 
located close to each other, a single PCR reaction was performed to detect binding on these 
sites. Although the GC-rich character of the uch l1 promoter sequence somewhat impeded 
PCR reactions for sites 4/5, binding was detected at the combined sites. Additionally, we 
also performed PCR for a region 1500 bp upstream of site 1 on the uch l1 promoter as a 
control for non-specific binding. Our ChIP results demonstrate that PU.1 could bind to at 
least three of the five sites on the uch l1 promoter.
To confirm that PU.1 induces uch l1 promoter activity through its binding sites, we made 
site-directed mutations in the parental uch l1 promoter plasmid by creating a total of five uch 
l1 promoter plasmids, each with single-site mutations, and an additional construct in which 
all five PU.1 binding sites were mutated from GGAA to CTTC. An identical mutation was 
previously shown to prevent binding of PU.1 to the cathepsin G gene [40]. We then 
examined how these mutations affected PU.1’s ability to activate the uch l1 promoter. NIH 
3T3 cells were co-transfected with control or pECE-PU.1 expression plasmid, along with 
either wild-type or mutated UCHL1p-LUC construct. All luciferase assays were performed 
as described in ‘Materials and methods.’ We found that PU.1 induced the wild-type uch l1 
reporter construct by 2.5-fold. Additionally, while individual mutation in each PU.1 binding 
site reduced promoter activity, there was a more profound inhibitory effect when all five PU.
1 binding sites were mutated [Figure 3(B)]. These results indicate that the expression of 
UCH L1 is regulated directly by PU.1.
UCH L1 expression is up-regulated in primary B-lymphocytes immortalized with EBV
Previous studies have shown that EBV-transformed peripheral blood mononuclear cells 
(PBMCs) analyzed after 90 days of infection had increased the enzymatic activity of at least 
six cellular deubiquitinating enzymes (DUBs) including UCH L1 [41]. To investigate how 
UCH L1 expression is increased in such cells upon EBV infection, we examined the 
expression of UCH L1 in two sets of PBMCs before and after EBV infection [Figure 4(B)]. 
UCH L1 was not detected in primary PBMCs; however, it was readily detectable at high 
levels in the EBV-transformed cells. Thus, upregulation of UCH L1 RNA [Figure 4(A)] and 
protein levels [Figure 4(B)] after EBV immortalization likely accounts for the increased 
UCH L1 activity.
Infection of Burkitt lymphoma cells with EBV further increases UCH L1 expression
We next investigated whether the induction was related to EBV products expressed during 
type III EBV latency. African Burkitt lymphomas are characterized by translocations that 
activate the expression of c-myc and are almost always EBV-positive. The basal levels of 
UCH L1 are elevated in such lines [41]. Rarely, Burkitt lymphoma (BL) and cell lines 
derived from them are EBV-negative, but they can be infected with EBV in vitro. We took 
advantage of one such cell line, BL30, and its B95.8-infected counterpart, BL30-EBV [42], 
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to compare endogenous levels of UCH L1 and then to determine whether EBV type III 
latency products affect UCH L1 expression. First, we examined whether the type III latency 
state of BL30-EBV cells would alter basal uch l1 promoter activity by comparing activity in 
these two cell lines with the use of UCHL1p-LUC construct [19]. As shown in Figure 5(A), 
uch l1 promoter activity is higher in EBV-positive BL30 cells.
We next analyzed UCH L1 RNA and protein levels in these cell lines with QRT-PCR and 
Western blot analysis. Although UCH L1 RNA [Figure 5(B)] and protein [Figure 5(C)] were 
readily detectable in EBV-negative BL30 cells, levels were consistently higher in EBV-
infected cells. To further confirm that changes observed in UCH L1 expression were due to 
EBV products and not due to changes in PU.1 expression, we analyzed PU.1 RNA and 
protein levels in these cell lines with QRT-PCR and Western blot analysis. Previous studies 
[43,44] and our data indicate that PU.1 expression does not change with EBV infection of B-
cells [Figures 5(D) and 5(E)].
The results with these representative cell lines indicate that in BL cells, whether infected 
with EBV or not, UCH L1 levels are elevated. These results also show that EBV infection of 
BL30 cells induced uch l1 promoter activity and further increased UCH L1 expression, 
presumably due to EBV type III latency products.
PU.1 forms endogenous complex with EBNA2 and induces endogenous UCH L1 
expression
Our results suggest that one or more type III EBV latency products increase UCH L1 
expression in EBV-immortalized B-cells. It has been shown that EBNA2 interacts with PU.1 
and plays an important role in EBNA2-mediated transcriptional activation [34,35]. To 
confirm the interaction between EBNA2 and PU.1, we performed IP with PU.1 antibody 
from KR4 LCLs. Association between EBNA2 and PU.1 was detected by performing 
Western blot analysis for EBNA2 [Figure 6(A)]. We tested whether EBNA2 activates the 
uch l1 promoter by co-transfecting NIH 3T3 cells with PU.1 or EBNA2-HA, or EBNA2-HA 
and PU.1 together, or control plasmid along with UCHL1p-LUC reporter or UCHL1p-LUC 
construct mutated at all five PU.1 binding sites [Figure 6(B)]. While EBNA2 and PU.1 
separately activated the wild-type uch l1 promoter to a modest level, co-expression of 
EBNA2 and PU.1 resulted in synergistic activation of the promoter, indicating that EBNA2 
acts as a transcriptional co-activator for PU.1. However, PU.1 was not able to induce the uch 
l1 promoter mutated at all five PU.1 sites. EBNA2 by itself slightly increased activity of the 
mutated promoter but not as strongly as the wild-type uch l1 promoter. In the case of 
EBNA2 and PU.1 co-expression, induction was reduced by 50% as compared with wild-
type uch l1 promoter [Figure 6(B)].
We next investigated whether EBNA2 and PU.1 induces endogenous UCH L1 expression in 
NIH 3T3 cells, which express very low levels of this enzyme. Although expression of 
EBNA2 and PU.1 separately did not induce detectable levels of endogenous UCH L1 (data 
not shown), together they substantially increased UCH L1 expression at both RNA and 
protein levels [Figures 6(C) and 6(D)]. These data indicate that PU.1 and EBNA2 cooperate 
in up-regulation of UCH L1 expression.
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Inhibition of PU.1 in B-lymphoma cells reduces endogenous UCH L1 expression
To validate the role of PU.1 as a hematopoietic transcription factor for UCH L1 expression 
in lymphoid cells, we suppressed PU.1 levels in EBV-transformed B-cells with specific 
shRNA (Figure 7). Inhibition of endogenous PU.1 expression resulted in visible reduction of 
endogenous UCH L1 RNA [Figure 7(A)] and protein [Figure 7(B)] levels. In addition, the 
analysis of UCH L1 expression in LCLs stably expressing second PU.1 shRNA confirmed 
these results (data not shown). These results demonstrate that PU.1 contributes to the UCH 
L1 expression in B-lymphoma cells.
Discussion
Several recent studies provide evidence that UCH L1 is an oncogene involved in the 
development of certain types of lymphoma [13,14,16], raising the question whether its 
expression in lymphoid malignancies can be regulated by specific lymphoid factors. In this 
study we show that the myeloid/lymphoid transcription factor PU.1 contributes substantially 
to UCH L1 expression in B-lymphoma cell lines. The addition of PU.1 to putative binding 
site oligonucleotides generated slowly migrating PU.1/uch l1 promoter complexes (Figure 
2), indicating that PU.1 induces the uch l1 gene through direct binding to specific sites on 
the uch l1 promoter. Since there are five PU.1 binding sites, it is possible that PU.1 may 
bind competitively or sequentially to these sites, and we believe that further analysis of these 
sites is required to determine the binding affinity of PU.1 on each site. It is important to note 
that competition assays were not performed, because SYBR green will stain any free DNA 
and will interfere with DNA gel analysis.
The ChIP analysis showed that PU.1 forms an endogenous complex on the uch l1 promoter 
[Figure 3(A)]. While mutations in single PU.1 binding sites reduced PU.1-mediated 
induction of the uch l1 promoter, mutations in all five PU.1 sites practically abolished PU.1-
dependent activation [Figure 3(B)]. We suggest that PU.1 binding sites can complement 
each other in PU.1-mediated induction of the uch l1 promoter. PU.1 is known to regulate 
gene expression in a dose-dependent manner, and levels of PU.1 determine whether 
progenitor cells will differentiate into lymphoid or myeloid origin [22,45]. Interestingly, we 
observed that lower concentrations (up to 250 ng/well) of PU.1 induced uch l1 promoter 
activity whereas higher concentrations (more than 500 ng/well) of PU.1 rather inhibited 
activity (data not shown). PU.1 is not the only example of such concentration-dependent 
effects: low or high concentrations of p53 transcription factor can inhibit or activate the 
epidermal growth factor receptor (EGFR) promoter [46]. It is possible that multiple PU.1 
binding sites on the uch l1 promoter are associated with different levels of UCH L1 
expression during the process of hematopoietic differentiation. It will also be interesting to 
see whether PU.1 occupies the same sites on the uch l1 promoter in cells of lymphoid versus 
myeloid origin.
Tumor viruses are important oncogenic agents, and EBV is prominently linked to lymphoid 
cancers: after establishing latent infection in B-cells, EBV latency products dysregulate 
major signaling pathways, which results in cell transformation [30,47]. Our study shows that 
immortalization of primary B-cells induces, and infection of Burkitt lymphoma cells by 
EBV increases, UCHL1 expression (Figures 4 and 5). These results complement those of 
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previous studies showing that UCH L1 deubiquitinating activity is increased in EBV-
transformed cells [41]. We do not know whether expression of UCH L1 induced after EBV 
immortalization is a result of EBV infection alone or due to other factors, a subject of 
interest for future studies. However, we think that the physiological effect of EBV-mediated 
up-regulation of the uch l1 gene in EBV-infected B-cells is probably not induction of the 
initial UCH L1 expression, but rather preservation of certain levels of UCH L1 protein after 
immortalization, and as a result, maintenance of the transformed status of the cells [14].
Various transcriptional factors, including viral, have been identified as interaction partners 
of PU.1 in positive or negative regulation of transcription [48]. Partners of PU.1 include c-
Jun and c-Fos (co-activators), C/EBP-δ (synergistic), AML-1/ETO (antagonistic), c-Myb 
(cooperative), and EBNA2 viral protein (synergistic) [34,48]. Our results show that co-
expression of PU.1 and EBNA2 activates the uch l1 promoter construct more vigorously 
than does either factor separately [Figure 6(B)]. More important, together PU.1 and EBNA2 
induce endogenous UCH L1 expression in cells that do not express either of these products 
[Figure 6(C)]. For now we can only speculate that either over-expressed PU.1/EBNA2 
complex has greater ability than PU.1 alone to transactivate the promoter or that co-
expression of EBNA2 initiates a synergistic chain of events that activates the uch l1 
promoter indirectly, through other transcription factors. The uch l1 promoter has binding 
sites for other transcription factors such as c-Jun/c-Fos, GATA2, and c-Myb, which are 
known to be PU.1 partners also, that might be playing a role in regulation of the promoter 
[48]. Additionally, the uch l1 promoter has binding sites for other oncogenic transcription 
factors such as nuclear factor κB (NFκB), AP2, E2F4, and POU, which we believe might 
participate in inducing UCH L1 expression in transformed cells in the absence of EBV 
infection.
We show that suppression of endogenous levels of PU.1 in B-lymphoma cell lines reduces 
UCH L1 expression (Figure 7), which confirms that PU.1 is indeed a positive regulator of 
the uch l1 gene at physiological levels. We think that suppression of UCH L1 expression is 
decreased by 40% because of interplay with other transcription factors. It is also important 
to note that SpiB, an isoform of PU.1, is expressed in B-cells, and can bind to PU.1 binding 
sites to mediate transcription [49]. We believe that SpiB works as a compensatory 
mechanism to maintain UCH L1 expression in EBV-transformed cells in the absence of PU.
1.
In addition to PU boxes the uch l1 promoter contains binding sites for several oncogenic 
transcription factors such as AP-1 and c-Myc. Since translocation and constitutive 
expression of c-Myc is a hallmark of Burkitt lymphomas [50–52], c-Myc-dependent 
activation of the uch l1 gene might be one of the reasons why UCH L1 levels are elevated in 
primary EBV-negative Burkitt lymphoma cells (Figure 5). To summarize our findings, we 
put forward a simplified model of a mechanism for uch l1 promoter activation by PU.1 
(Figure 8). PU.1 and its partners enhance PU.1-mediated induction of the uch l1 promoter in 
transformed B-cells. Since PU.1 is a hematopoietic-specific transcription factor, implication 
of PU.1 in direct regulation of the uch l1 promoter accounts at least in part for UCH L1 
expression in lymphoid cancers, including EBV-associated lymphomas.
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The observation that UCH L1 expression is significantly greater in B-lymphoma cells 
compared with transformed cells of non-lymphoid origin (Figure 1) suggests that UCH L1 
might play a specific role in the development or progression of lymphoid malignancies. 
Increased motility is one of the basic characteristics of invasive lymphoid cancers [53–55]. 
Dynamic changes in cell shape during adhesion and migration are tightly controlled by the 
lymphoid cell cytoskeletal network [56–61], and recent studies implicate UCH L1 in 
regulation of cytoskeletal dynamics [7,8]. These observations might explain the high levels 
of UCH L1 in such malignancies, and highlight this multifunctional protein of the ubiquitin 
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High levels of UCH L1 protein detected in B-lymphoma cells. Total cell lysates from four 
epithelial (U2OS, 293, HeLa, and C33A, lanes 1–4), four fibroblastic (NIH3T3, GM0010A, 
Cos7, and GM00637F, lanes 5–8), and four B-lymphoblastoid (BL30, X-50/7, KR4, and 
Raji, lanes 9–12) cell lines were separated in SDS-PAGE and probed with UCH L1 and 
GAPDH antibodies.
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PU.1 directly binds to the uch l1 promoter at each of five PU.1 sites in vitro. (A) Schematic 
illustration of uch l1 promoter with five putative PU.1-binding sites. (B) Purified 
recombinant PU.1 separated on SDS-PAGE and detected with Coomassie blue stain; 4 µg of 
BSA was used as loading control. (C) High molecular weight DNA-protein complexes of 
uch l1 promoter and PU.1 stained with SYBR green EMSA to visualize DNA. (D) Western 
blot analysis was performed on the same gel for visualization of PU.1 in complex with uch 
l1 promoter with PU.1 antibody.
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Mutations in PU.1-binding sites abolish PU.1-mediated activation of the uch l1 promoter. 
(A) ChIP/PCR analysis was performed to determine binding of PU.1 factor to the putative 
binding sites on uch l1 promoter with the use of specific PU.1 antibody in KR4 LCLs. 
Normal IgG was used as negative control in immunoprecipitations. PCR reactions were 
performed with primers targeting PU.1-binding sites (see ‘Materials and methods’), and 
amplified DNA products were resolved in 2% agarose gel. (B) NIH 3T3 cells were co-
transfected with control or PU.1 (250 ng/well) expression vectors, along with UCHL1p–
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LUC wild-type and mutant reporter plasmids (500 ng/well). Luciferase assays were 
performed 48 h post-transfection. The data represent three independent experiments 
prepared in triplicate and normalized to β-galactosidase activity.
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UCH L1 expression is induced in primary B-cells after EBV immortalization. Total RNA 
and protein were extracted from uninfected PMBCs from two donors (I and II) and from the 
same PBMCs after EBV immortalization. (A) Reverse-transcription PCR analysis was 
performed with UCH L1-specific primers and GAPDH primers used as internal control. (B) 
Western blot analysis was performed with UCH L1 antibody. β-Actin served as loading 
control.
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Type III EBV latency products induce UCH L1 expression in a Burkitt lymphoma cell line 
latently infected with EBV. uch l1 promoter activity was determined in paired uninfected 
and EBV-infected BL30 cell lines. (A) Cells (2 × 105) were nucleofected with UCHL1p–
LUC reporter construct. Luciferase assays were performed 48 h post-transfection. The data 
represent three independent experiments prepared in triplicate and normalized to β-
galactosidase activity. (B) Total RNA was extracted from BL30 and BL30-EBV cells, and 
real-time PCR analysis with specific primers for UCH L1 was performed. GAPDH was used 
as internal control. (C) Western blot analysis for UCH L1 protein levels in lysates from 
BL30 and BL30-EBV cells was performed with UCH L1 antibody. GAPDH was used as 
loading control. Quantification is shown for UCH L1 protein expression. (D) Total RNA 
was extracted from BL30 and BL30-EBV cells, and real-time PCR analysis with specific 
primers for PU.1 was performed. GAPDH was used as internal control. (E) Western blot 
analysis for UCH L1 protein levels in lysates from BL30 and BL30-EBV cells was 
performed with PU.1 antibody. GAPDH was used as loading control.
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PU.1 and EBNA2 form endogenous complex and synergistically induce endogenous UCH 
L1 expression. (A) PU.1 was immunoprecipitated from total lysates of KR4 LCLs, IPs were 
resolved in 12% PAGE and probed with EBNA2 antibody. Rabbit normal immunoglobulins 
were used as control for IPs. (B) NIH 3T3 cells (low endogenous level of UCH L1) were 
used for all experiments. Cells were co-transfected with control (1000 ng/well) or PU.1 (250 
ng/well) or EBNA2-HA (750 ng/well) or EBNA2-HA (750 ng/well) and PU.1 (250 ng/well) 
together, along with UCHL1p–LUC wild-type or with five PU.1 binding sites mutated (500 
ng/well). Control DNA was used as filler where necessary. Luciferase assays were 
performed 48 h post-transfection and are normalized to β-galactosidase activity. (C) Next, 
cells were co-transfected with EBNA2-HA (750 ng/well) and PU.1 (250 ng/well) expression 
vector or control. Total RNA and protein were extracted 48 h post-transfection, RT-PCR 
was performed to detect expression of UCH L1 RNA levels with UCH L1-specific primers. 
(D) Western blot analysis was used to detect endogenous UCH L1 protein levels with UCH 
L1 antibody. GAPDH served as loading control.
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Inhibition of PU.1 expression results in reduction of UCH L1 levels in transformed B-cells. 
PU.1 shRNA or GFP shRNA was stably nucleofected in the EBV-transformed B-cell line 
KR4. Cells were selected and maintained in medium with puromycin (1 µg/mL). (A) Total 
RNA was extracted from cells expressing GFP shRNA and PU.1 shRNA, and real-time PCR 
analysis with specific primers for PU.1 and UCH L1 was performed. GAPDH was used as 
internal control. (B) Western blot analysis for UCH L1 protein levels was performed in cell 
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lysates from cells expressing GFP shRNA and PU.1 shRNA with PU.1 and UCH L1 
antibody. GAPDH was used as loading control.
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Working model: PU.1 up-regulates uch l1 expression in B-cell lymphomas. In B-
lymphomas, the hematopoietic specific factor PU.1 induces UCH L1 expression. Induced 
expression of UCH L1 is then used to activate oncogenic pathways [14].
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